[go: up one dir, main page]

MXPA04011937A - Oligonucleotidos inmunoestimuladores y sus usos. - Google Patents

Oligonucleotidos inmunoestimuladores y sus usos.

Info

Publication number
MXPA04011937A
MXPA04011937A MXPA04011937A MXPA04011937A MXPA04011937A MX PA04011937 A MXPA04011937 A MX PA04011937A MX PA04011937 A MXPA04011937 A MX PA04011937A MX PA04011937 A MXPA04011937 A MX PA04011937A MX PA04011937 A MXPA04011937 A MX PA04011937A
Authority
MX
Mexico
Prior art keywords
stimulation
immune response
cytokine production
immunostimulatory oligonucleotides
differentiation
Prior art date
Application number
MXPA04011937A
Other languages
English (en)
Inventor
Ricardo Agustin Lopez
Original Assignee
Immunotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotech Sa filed Critical Immunotech Sa
Publication of MXPA04011937A publication Critical patent/MXPA04011937A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)

Abstract

Oligonucleotidos que contienen la secuencia no palindromica X1X2X3X4X5X6X7X8 donde X1 ES C o T, X2 es C, T, G o A, X3 es T o A, X4 es T, C o G, X5 es T, C o G, X6 es T o G, X7 es G, y X8 es T y donde por lo menos dos de X3X4X5 y X6 son Ts y donde C nunca precede a G (en otros terminos, el fragmento de acido nucleico no consiste de oligonucleotidos CpG) y que tienen la capacidad de estimular la respuesta inmune de los animales de la orden Primate, incluyendo humanos. La estimulacion de la respuesta inmune esta caracterizada por la estimulacion de la proliferacion, diferenciacion, produccion de citocinas y de anticuerpos en celulas B y la diferenciacion celular y produccion de citocinas en celulas dentriticas plasmacitoides.
MXPA04011937A 2002-05-30 2003-05-30 Oligonucleotidos inmunoestimuladores y sus usos. MXPA04011937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002388049A CA2388049A1 (en) 2002-05-30 2002-05-30 Immunostimulatory oligonucleotides and uses thereof
PCT/EP2003/005691 WO2003101375A2 (en) 2002-05-30 2003-05-30 Immunostimulatory oligonucleotides and uses thereof

Publications (1)

Publication Number Publication Date
MXPA04011937A true MXPA04011937A (es) 2006-06-27

Family

ID=29589083

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04011937A MXPA04011937A (es) 2002-05-30 2003-05-30 Oligonucleotidos inmunoestimuladores y sus usos.

Country Status (14)

Country Link
US (4) US7038029B2 (es)
EP (1) EP1511845B1 (es)
JP (1) JP4568907B2 (es)
KR (1) KR20050005521A (es)
AT (1) ATE541039T1 (es)
AU (1) AU2003250334B2 (es)
CA (1) CA2388049A1 (es)
CY (1) CY1112588T1 (es)
DK (1) DK1511845T3 (es)
ES (1) ES2380796T3 (es)
MX (1) MXPA04011937A (es)
NZ (1) NZ536962A (es)
PT (1) PT1511845E (es)
WO (1) WO2003101375A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2244946C (en) * 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
EP1350262B8 (en) * 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-like nucleic acids and methods of use thereof
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
JP2005519035A (ja) * 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
FR2848565B1 (fr) * 2002-12-16 2007-04-06 Ets Francais Du Sang Lignee de cellules dendritiques gen2.2
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
EP1642585A1 (en) * 2004-09-27 2006-04-05 Immunotech S.A. Osteogenic oligonucleotides and uses thereof
EP1657307A1 (en) * 2004-11-16 2006-05-17 Immunotech S.A. Oligonucleotides that induce the secretion of GM-CSF
KR100740237B1 (ko) * 2005-05-10 2007-07-18 아이진 주식회사 올리고뉴클레오타이드 및 비독성 다당체를 포함하는면역보조제
EP1728514A1 (en) * 2005-06-03 2006-12-06 Immunotech S.A. Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation
WO2007089051A1 (en) * 2006-02-01 2007-08-09 Eyegene Inc. Composition for treating cancer comprising oligonucleotide and non-toxic lps
DK2056845T3 (da) 2006-08-08 2017-11-27 Rheinische Friedrich-Wilhelms-Universität Bonn Struktur og anvendelse af 5'-phosphat-oligonukleotider
CN101517082B (zh) 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
EP2338499A1 (en) 2006-10-10 2011-06-29 Gunther Hartmann 5' triphosphate oligonucleotide induces anti-viral response
EP2209476A4 (en) * 2007-04-19 2011-01-19 Univ Pittsburgh USE OF TOLL-LIKE RECEPTOR 9 AGONISTS; TOLL-LIKE RECEPTOR-4 ANTAGONISTS AND / OR NUCLEAR OLIGOMERIZATION DOMAIN-2-AGONSITES FOR TREATING OR PREVENTING DISEASES RELATED TO TOLL-LIKE RECEPTOR-4
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
MX349720B (es) 2008-06-27 2017-08-09 Zoetis Services Llc Composiciones adyuvantes novedosas.
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CN102439153B (zh) 2009-03-25 2015-07-22 德克萨斯大学系统董事会 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
EP2757988A4 (en) 2009-06-15 2015-08-19 Jackson Roger P POLYAXIAL BONE ANCHORING DEVICE WITH PRESSURE-INPUT ROD AND FRICTION-ADJUSTING COMPRESSION-SIZE CLAMP FIN
EP2485654B1 (en) 2009-10-05 2021-05-05 Jackson P. Roger Polyaxial bone anchor with non-pivotable retainer and pop-on shank, some with friction fit
CA2791025A1 (en) 2010-02-25 2011-09-01 Duke University Method of inducing the production of protective anti-hiv-1 antibodies
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
AU2011324058A1 (en) 2010-11-02 2013-06-20 Roger P. Jackson Polyaxial bone anchor with pop-on shank and pivotable retainer
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
US9562066B2 (en) 2012-09-25 2017-02-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
JP6586083B2 (ja) 2013-09-19 2019-10-02 ゾエティス・サービシーズ・エルエルシー 油性アジュバント
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
PL3164113T3 (pl) 2014-06-04 2019-09-30 Exicure, Inc. Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP2017537619A (ja) 2014-11-21 2017-12-21 ノースウェスタン ユニバーシティ 球状核酸ナノ粒子複合体の配列特異的細胞内取込
LT3244920T (lt) 2015-01-16 2023-08-25 Zoetis Services Llc Snukio ir nagų ligos vakcina
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
JP2021512144A (ja) * 2018-01-26 2021-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｃａｌｉｆｏｒｎｉａ 環状ジヌクレオチドアジュバント含有結核ワクチンの鼻腔内送達
US20210040447A1 (en) * 2018-02-26 2021-02-11 Claudia Zylberberg Immune cell activation
WO2022094102A1 (en) * 2020-10-30 2022-05-05 Mid-Atlantic Biotherapeutics, Inc. Immunostimulatory oligonucleotides for the prevention and treatment of covid-19

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
DE69432375T2 (de) * 1993-04-30 2004-02-12 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense Oligonukleotide zur Behandlung von immunsuppressiven Wirkungen von TGF-beta2
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
CA2560114A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5968909A (en) * 1995-08-04 1999-10-19 Hybridon, Inc. Method of modulating gene expression with reduced immunostimulatory response
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
PT1005368E (pt) 1997-03-10 2009-11-19 Coley Pharm Gmbh Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante
AU7589398A (en) 1997-05-19 1998-12-11 Merck & Co., Inc. Oligonucleotide adjuvant
CA2301575C (en) * 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
ES2326848T3 (es) * 1997-06-06 2009-10-20 The Regents Of The University Of California Inhibidores de la actividad de secuencias inmunoestimulatorias de adn.
FR2773032B1 (fr) 1997-12-22 2001-12-21 Nortel Matra Cellular Modulation d'un signal numerique a spectre etroit et a enveloppe sensiblement constante
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
JPH11209289A (ja) * 1998-01-22 1999-08-03 Taisho Pharmaceut Co Ltd 粘膜免疫誘起剤
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2328602A1 (en) 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
EP1108017A2 (en) 1998-09-03 2001-06-20 Coley Pharmaceutical GmbH G-motif oligonucleotides and uses thereof
US6497360B1 (en) 2000-07-26 2002-12-24 In-Store Media Systems, Inc. Prompt coupon reimbursement after coupon redemption
WO2000061151A2 (en) 1999-04-12 2000-10-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CZ303515B6 (cs) 1999-04-19 2012-11-07 Smithkline Beecham Biologicals S. A. Adjuvantní prostredek
HK1045099A1 (zh) 1999-04-20 2002-11-15 Smithkline Beecham Biologicals S.A. 含有rsv抗原和cpg寡核苷酸的疫苗
AU4978100A (en) * 1999-04-29 2000-11-17 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers
CA2372960C (en) 1999-05-06 2006-03-28 The Immune Response Corporation Hiv immunogenic compositions and methods
NZ515957A (en) 1999-06-08 2003-08-29 Aventis Pasteur Immunostimulant oligonucleotide
WO2001000232A2 (en) 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
GB9915204D0 (en) 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
AU6605200A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
DK1200580T3 (da) 1999-08-13 2005-04-11 Hybridon Inc Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
TR200200797T2 (tr) 1999-09-25 2002-10-21 University Of Iowa Research Foundation İmmünostimülatör nükleik asitler
NZ517928A (en) 1999-09-27 2004-09-24 Coley Pharm Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
JP2003514791A (ja) 1999-11-02 2003-04-22 カイロン コーポレイション 二本鎖ＲＮＡレセプター（ｄｓＲＮＡ−Ｒ）およびそれに関連する方法
US7355092B2 (en) 1999-12-27 2008-04-08 Ronald Marquardt Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic Escherichia coli and other pathogens
WO2001051083A2 (en) 2000-01-13 2001-07-19 Antigenics Inc. Innate immunity-stimulating compositions of cpg and saponin and methods thereof
WO2001095935A1 (en) * 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
ATE382690T1 (de) 2000-01-26 2008-01-15 Idera Pharmaceuticals Inc Modulierung der durch cpg-oligonukleotide verursachte immunstimulierung durch positionsbedingte veränderung von nukleosiden
EP1253947A4 (en) 2000-01-31 2005-01-05 Univ California IMMUNOMODULATORY POLYNUCLEOTIDES FOR THE TREATMENT OF INFECTION BY AN INTRACELLULAR PATHOGEN
FR2805265B1 (fr) 2000-02-18 2002-04-12 Aventis Pasteur Oligonucleotides immunostimulants
FR2805264B1 (fr) 2000-02-18 2002-04-12 Aventis Pasteur Oligonucleotides immunostimulants
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
EP1263773A4 (en) 2000-03-14 2005-08-31 Active Motif OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF IMPLEMENTATION
EP1278761B1 (en) 2000-05-01 2005-04-06 Hybridon, Inc. MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
US8568742B2 (en) 2000-06-08 2013-10-29 Valneva Austria Gmbh Methods and compositions involving immunostimulatory oligodeoxynucleotides
US20020165178A1 (en) * 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020198165A1 (en) * 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
EP1335741A4 (en) 2000-08-25 2005-10-26 Yeda Res & Dev METHOD FOR THE PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDES (04.03.02)
KR100865706B1 (ko) * 2000-09-26 2008-10-28 이데라 파마슈티칼즈, 인코포레이티드 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP1350262B8 (en) 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-like nucleic acids and methods of use thereof
FR2819724B1 (fr) 2001-01-22 2005-05-13 Inst Necker Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
WO2002094845A2 (en) 2001-05-21 2002-11-28 Intercell Ag Method for stabilising of nucleic acids
GB0114719D0 (en) 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
CZ20033515A3 (cs) 2001-06-29 2005-01-12 Chiron Corporation Kompozice vakcíny HCV E1E2
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US7318313B2 (en) 2003-01-31 2008-01-15 Freni Brembo S.P.A. Switch

Also Published As

Publication number Publication date
US20130243811A1 (en) 2013-09-19
US20040006032A1 (en) 2004-01-08
US20090060937A1 (en) 2009-03-05
ES2380796T3 (es) 2012-05-18
US7381807B2 (en) 2008-06-03
PT1511845E (pt) 2012-04-13
WO2003101375A3 (en) 2004-09-02
KR20050005521A (ko) 2005-01-13
JP4568907B2 (ja) 2010-10-27
US7038029B2 (en) 2006-05-02
AU2003250334B2 (en) 2008-06-05
US20050276789A1 (en) 2005-12-15
ATE541039T1 (de) 2012-01-15
EP1511845B1 (en) 2012-01-11
US8871436B2 (en) 2014-10-28
AU2003250334A1 (en) 2003-12-19
NZ536962A (en) 2006-09-29
WO2003101375A2 (en) 2003-12-11
JP2005533491A (ja) 2005-11-10
DK1511845T3 (da) 2012-05-07
EP1511845A2 (en) 2005-03-09
CA2388049A1 (en) 2003-11-30
US7943316B2 (en) 2011-05-17
CY1112588T1 (el) 2016-02-10

Similar Documents

Publication Publication Date Title
MXPA04011937A (es) Oligonucleotidos inmunoestimuladores y sus usos.
GR3024597T3 (en) 7-deazapurine modified oligonucleotides
IL160157A (en) Combination motif immune stimulatory oligonucleotides with improved activity
UA88457C2 (ru) Иммуностимулирующая нуклеиновая кислота с улучшенной иммуностимулирующей эффективностью
BG101103A (bg) Теломераза при бозайници
EP2397549A3 (en) Non-stochastic generation of genetic vaccines and enzymes
CA2325351A1 (en) Non-stochastic generation of genetic vaccines and enzymes
EP2314693A3 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
WO2004002417A3 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
MY165643A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1714969A3 (en) Immunostimulatory nucleic acid molecules
EP2415481A3 (en) Immunostimulatory viral RNA oligonucleotides
EP2292632A3 (en) Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
AU2002339458A1 (en) Sirna knockout assay method and constructs
EP2090657A3 (en) Anti-IL-12 antibodies, compositions, methods and uses
DE69736840D1 (de) Synthese von nukleosiden und polynukleotiden
WO2000053776A3 (en) Human kallikrein-like genes
WO2000030667A3 (en) Compositions and methods using lactadherin or variants thereof
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO2003031459A3 (de) Modulation der expression stat-1-abhängiger gene
PT1383796E (pt) Estirpe neurovirulenta do vírus do nilo ocidental e as suas aplicações
WO2003031620A1 (fr) Nouveau recepteur des cytokines de classe ii
CA2287902A1 (en) Isolated nucleic acid molecules encoding ssx family members and uses thereof
PT1537210E (pt) Inibicao de oliconucleotidos decoy de expressao cd-40
ATE346855T1 (de) Immobilisierung von oligonukleotiden an feste träger

Legal Events

Date Code Title Description
FG Grant or registration